ストックスクリーナーアプリを入手
70.09
1.03%
-0.73
前日終値:
$70.82
開ける：
$70.82
24時間の取引高:
1.55M
Relative Volume:
0.65
時価総額：
$9.52B
収益：
$181.74M
当期純損益:
$-143.97M
株価収益率:
-50.42
EPS:
-1.39
ネットキャッシュフロー:
$9.60M
1週間 パフォーマンス:
+14.08%
1か月 パフォーマンス:
+69.22%
6か月 パフォーマンス:
+332.12%
1年 パフォーマンス:
+216.58%
1日の値動き範囲:
$68.01
$71.00
1週間の範囲:
$65.40
$72.36
52週間の値動き範囲:
$9.57
$72.36
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
名前
Arrowhead Pharmaceuticals Inc
セクター
電話
626-696-4702
住所
177 E COLORADO BLVD, PASADENA, CA
ARWR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
70.09 | 9.62B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-05 | 開始されました | Goldman | Neutral |
| 2023-12-04 | 開始されました | BofA Securities | Buy |
| 2023-09-19 | 開始されました | Citigroup | Neutral |
| 2023-07-21 | 開始されました | TD Cowen | Outperform |
| 2023-05-12 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-12 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-11 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 再開されました | Goldman | Buy |
| 2021-08-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-11-19 | 開始されました | Citigroup | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-05-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-04-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 開始されました | Goldman | Neutral |
| 2020-01-21 | 開始されました | SVB Leerink | Underperform |
| 2019-12-13 | 開始されました | Oppenheimer | Perform |
| 2019-11-29 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-27 | 繰り返されました | B. Riley FBR | Buy |
| 2019-11-25 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-10-03 | 開始されました | Robert W. Baird | Outperform |
| 2018-09-07 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-08-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Arrowhead Pharmaceuticals Inc (ARWR) 最新ニュース
WINTON GROUP Ltd Invests $660,000 in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN
RBC Capital Maintains Arrowhead Pharmaceuticals (ARWR) Outperform Recommendation - Nasdaq
Arrowhead Pharma (ARWR) Receives Raised Price Target from RBC Capital | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals stock hits 52-week high at 71.62 USD - Investing.com
Arrowhead Pharma stock price target raised to $80 from $52 at RBC Capital - Investing.com Canada
Arrowhead Pharmaceuticals (ARWR) Valuation Check as ARO-MAPT Enters First Human Trial in Alzheimer’s Treatment - Yahoo Finance
History Review: Can Arrowhead Pharmaceuticals Inc stock surprise with earnings upsideJuly 2025 Closing Moves & Verified Momentum Stock Watchlist - moha.gov.vn
B of A Securities Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - Nasdaq
ARWR: B of A Securities Raises Price Target Amid Maintained Buy Rating | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial - ts2.tech
Arrowhead Pharmaceuticals Flourishes with Key Milestones and Growth Projections - StocksToTrade
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins - ts2.tech
Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals stock soars after dosing first subjects in trial - Investing.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 1-Year HighTime to Buy? - MarketBeat
Arrowhead Hits the Mark - Los Angeles Business Journal
Arrowhead’s Plozasiran Garners FDA Breakthrough Recognition - timothysykes.com
Arrowhead (ARWR) Begins Trials for Alzheimer's Treatment - GuruFocus
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Business Wire
Marshall Wace LLP Grows Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Norges Bank Invests $30.41 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
(ARWR) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Edgestream Partners L.P. Lowers Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 5%What's Next? - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Price Target Increased by 17.24% to 59.24 - Nasdaq
Franklin Resources Inc. Purchases Shares of 81,226 Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (ARWR) and Humana (HUM) - The Globe and Mail
Arrowhead Pharmaceuticals (ARWR) Valuation After FDA Breakthrough Therapy Designation for Plozasiran - Sahm
How Arrowhead Pharmaceuticals Inc. (HDP1) stock reacts to Fed tighteningEarnings Recap Summary & Risk Managed Investment Entry Signals - Newser
How analysts revise price targets for Arrowhead Pharmaceuticals Inc. (HDP1) stockPortfolio Value Report & Reliable Price Breakout Alerts - Newser
Fisher Asset Management LLC Has $7.14 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
What dividend safety rating applies to Arrowhead Pharmaceuticals Inc. (HDP1) stockWeekly Loss Report & Long-Term Capital Growth Strategies - Newser
Is Arrowhead Pharmaceuticals Inc. (HDP1) stock cheap vs fundamentalsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Breakthrough Approved: FDA approves pioneering FCS drug by Pasadena company - Pasadena Weekly
HC Wainwright Issues Pessimistic Estimate for ARWR Earnings - MarketBeat
What is HC Wainwright's Estimate for ARWR Q2 Earnings? - MarketBeat
Why Arrowhead Pharmaceuticals Inc. (HDP1) stock is favored by hedge fundsJuly 2025 Summary & Low Drawdown Trading Strategies - Newser
Arrowhead Pharmaceuticals Poised for Growth Following Breakthrough FDA Approvals - StocksToTrade
ARWR’s Meteoric Rise: Can It Sustain? - timothysykes.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week High After Analyst Upgrade - MarketBeat
ARWR: Plozasiran launch, pipeline advances, and strong partnerships drive growth and innovation - TradingView
Arrowhead (ARWR) Stock Sees 9.7% Rise Following Market Activity - GuruFocus
Arrowhead Pharmaceuticals Soars with FDA Breakthrough Therapy Designation - timothysykes.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Arrowhead Pharma stock price target raised to $85 by H.C. Wainwright - Investing.com UK
Have Arrowhead Pharmaceuticals Insiders Been Selling Stock? - simplywall.st
Creative Planning Buys 19,194 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
How Arrowhead Pharmaceuticals Inc. (HDP1) stock behaves under inflation pressure2025 Valuation Update & Accurate Entry and Exit Point Alerts - Newser
Will Arrowhead Pharmaceuticals Inc. (HDP1) stock outperform global peers2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Mauro Ferrari Sells 8,750 Shares - MarketBeat
Arrowhead Pharmaceuticals Inc (ARWR) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):